Skin and oral lesions associated to imatinib mesylate therapy.

Introduction: Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects.

Results And Discussion: Skin rashes and oral lesions are uncommon and appear to be dose-dependent.